Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
One shouldn’t believe everything one reads on social media, especially when posted by an IRP.
LOL. Did they know of the "payer analysis" or did that catch them off guard too. Go B
It's aggravating that the research is positive:) Go scientists
It's even been posted to follow the science. If the study had found major side effects would there be this voracity to discredit the scientists. The testing so far has been very positive for IPIX. I take the scientists doing this research at their word no matter the outcome. Hoping for more good news.
Those studies are all based on pre-clinical work, aren't they? Do cells get measurable side effects that would allow for a statement like this?
I agree but I think it's good to remember that all this discovery is free to IPIX and at the same time building value. BP would likely not invest much if any in early research. Likely there's a lot going on we are not yet privy too. Time will tell.
NIH/NIAID keeps further expanding Brilacidin research. That's all I need to know. Go Killer B
This was just reported to share holders in a June23 pr "certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03)".
So there's evidence it can work when given early on.
It was understood that placebo was SOC.
Yes in a small subgroup it showed to work better then placebo such as remdesiver when given early before viral load has decimated patients. Luckily there were a few early on patients let in so that we now have this evidence.
"certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03)".
"In the need of reinforcing the drug repositioning strategy
and developing specific SARS-CoV-2 treatment, recently,
three main groups of scientists discovered that a new
antibacterial drug, named brilacidin, provides attractive
benefits against SARS-CoV-2, and specifically without
major side effects".
Oh but the tingling. lol
Thanks for posting. I saw you had posted the following in an earlier response..
"Steelyeye B will be licensed for individual indications starting with OM. As I indicated earlier that is why the "Payer Analysis" was run".
Looking for more on this thanks.
Both are in the business of developing medical treatments. Not coal or some other bull pucky you posted.
June 23, 2022
Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers
June 15, 2022
Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments through a New Image Guided Laser-Based Ablation Technology
“What Squalus is doing is truly revolutionary with the potential to help millions of patients around the world that are precluded from procedures to provide them relief from epilepsy and cancer because of the origin of their disease,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals".
http://www.ipharminc.com/press-release/2022/6/15/innovation-pharmaceuticals-acquires-stake-in-squalus-medical-seeks-to-reshape-cancer-and-epilepsy-treatments-through-a-new-image-guided-laser-based-ablation-technology
I see no divergence. Clearly Squalus Medical is in the medical field of which are advancing cancer and epilepsy treatment technology.
There is also the Fox Chase Payment deal. Early Anti-fungal investment deal so payment likely small imo.
Thanks for posting that PJ. B is getting a lot of new eyes on it for sure.
Now that's funny.
I will say holding onto all those class A shares even adding millions more put Kips Bay at a higher risk in a case of default compared to preferred shares. I also think it's a bullish move.
Nice move up. Good to see!
Posted this AM from Here Today regarding Kips Bay-
"I mean I can see if they filed that they liquidated all their shares and then did another purchase agreement, then yes, they would be considered a Toxic Lender.
But instead, they did the deal for the Class B shares which helped IPIX finance the Clinical Trial and company, and then held onto all those original converted shares of Class A shares which totaled 21,200,000 from 5/03/21. They could have sold and made a tremendous profit at anytime from 5/03/2021 until the results were released in November. But instead they held onto all their shares and have since more than doubled their Share Count!!! That to me is a bullish move expecting something to come'"
Exactly. It's important to say they hold their shares.
Remember the shutdown. Shutdowns are over hopefully now things can get back to speed. Patience is a virtue:)
They are an investment group.
Bullish move.
What?? The stock is too undervalued to short here. Btw who's doing the loaning and at what terms. Taking profit is a different story.
I don't agree with your long 5+ year time line for enema treatment to go to market. Patents are being expanded. B is being further patented as to compounding and surfactant additives. Hopefully funding comes.
http://www.ipharminc.com/press-release/2019/1/2/innovation-pharmaceuticals-receives-new-brilacidin-patent-further-expanding-intellectual-property-estate#:~:text=The%20%E2%80%9CIssue%20Notification%E2%80%9D%20of%20the%20patent%20%28Projected%20U.S.,The%20pharmaceutical%20composition%20can%20also%20contain%20Tris-buffered%20saline
AS would likely get new patents for B proctitis use i.e pharmaceutical composition change and drug delivery.
I'm following the thread. Some say Leo is just sitting around pool side. I don't believe that.
We are seeing the Blue Host server default page because the website is under construction and isn’t complete. Likely the owners in this case Squalusmed are building a completely new web page. Should be interesting.
Connecting dots...New hire...New patents...Payer analysis. What could be next a Term Sheet? Hmm Go B
Tough crowd lol
Exactly, you’re in the early stages of viral progression and within the parameters in which B could have stopped Covid in its tracks and the patient sent home but by the time most test patients were given B it was late in their disease progression the viral load had already waned and the damage to organs was complete. I think a lot of lessons learned from this study.
It was a 200% run on meaningful antiviral work but until we see detail funding news that launches us out of this fog it will be more of the same.
Money is still being allocated to searching out B's broad spectrum abilities so far it's over 20 viruses. Some may want you think there's no value here but why does the government keep allocating money if nothings being achieved.
Due to cancellation GMU did not do their presentation so we have a second shot. "Due to rising COVID-19 infections tied to the spread of SARS-CoV-2 variants, the U.S. Department of Defense (as the symposium sponsor) last Thursday cancelled the event that was to be held in Orlando, Florida. The Company will be discussing with George Mason University scientists, who were scheduled to present Brilacidin research on non-SARS-CoV-2 viruses, appropriate next steps for potential release of these findings".
IPIX/ George Mason University scientists is again invited this year to present. As an investor this is good news to get this second bite.
Yeah because it was cancelled due to covid-19 but you knew that.
Bunyaviruses and Alphaviruses next possibly Monkeypox testing?
Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium
It was unfortunate during that period the shut down lead to symposium being canceled but covid-19 is what got us here.
Like I said B seen as a broad spectrum countermeasure. A military contract would be fantastic.
The poster -- Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses
B seen as a broad spectrum countermeasure. A military contract would be fantastic.